EFFICACY AND TOLERABILITY OF DIFFERENT ORAL IRON PREPARATIONS IN IRON DEFICIENCY ANEMIA: REVIEW
Abstract
Background: iron deficiency anemia (IDA) is a widespread, preventable condition that diminishes work capacity, cognition, and overall health. Dysregulation of iron homeostasis — principally via hepcidin‑mediated sequestration — distinguishes absolute deficiency from functional deficiency, guides diagnostic interpretation and helps to choose the type therapy.
Aim: The aim of this article is to compare the available oral iron supplements with respect to efficacy, tolerability and practical use. It summarizes current evidence regarding optimal dosing and frequency of administration in individuals with iron deficiency and iron-deficiency anemia.
Methods: narrative review of literature up to 2025, prioritizing recent meta‑analyses, systematic reviews, randomized controlled trials, phase III randomized studies and other high‑quality studies. Searches were conducted in PubMed/MEDLINE, Embase, Web of Science and Google Scholar. Key search terms included oral iron, ferrous sulfate, liposomal iron, sucrosomial iron, ferric maltol and ferrous bisglycinate. This review compares their efficacy and tolerability. Study selection, data extraction, and quality evaluation followed standard review procedures; findings were synthesized and summarized in tables.
Results: new supplements generally achieve comparable or faster hematologic responses at lower elemental iron doses and are associated with fewer gastrointestinal side effects, which may improve adherence, particularly in patients intolerant of ferrous salts or with inflammatory conditions. Dosing approaches that account for hepcidin dynamics (alternate-day or single morning dosing) enhance absorption. Heterogeneity in study populations, dosing regimens and outcome measures limits direct comparisons.
Conclusion: oral iron formulations show broadly similar efficacy; selection should prioritize tolerability, comorbidity context, and dosing strategies that optimize absorption. Individualized therapy with routine monitoring of hemoglobin and ferritin improves outcomes and adherence.
References
Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW (2021) Iron deficiency. Lancet 397(10270): 233-248, https://doi.org/10.1016/S0140-6736(20)32594-0
Kolarš B, Mijatović Jovin V, Živanović N, Minaković I, Gvozdenović N, Dickov Kokeza I, Lesjak M. (2025) Iron Deficiency and Iron Deficiency Anemia: A Comprehensive Overview of Established and Emerging Concepts. Pharmaceuticals (Basel) 18(8): 1104. https://doi.org/10.3390/ph18081104
McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. (2009) Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutrition 12(4): 444-454. https://doi.org/10.1017/s1368980008002401
Camaschella C. (2015) Iron-Deficiency Anemia. The New England Journal of Medicine 373(5): 485-6, https://doi.org/10.1056/nejmc1507104
Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ. (2022) Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterology 9(1): e000759, https://doi.org/10.1136/bmjgast-2021-000759
Williams AM, Brown KH, Allen LH, Dary O, Moorthy D, Suchdev PS (2023) Improving Anemia Assessment in Clinical and Public Health Settings. The Journal of Nutrition 153(1): S29-S41, https://doi.org/10.1016/j.tjnut.2023.05.032
Pantopoulos K. (2024) Oral iron supplementation: new formulations, old questions. Haematologica 109(9): 2790-2801, https://doi.org/10.3324/haematol.2024.284967-
Schmidt C, Allen S, Kopyt N, Pergola P. (2021) Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion. Journal of Clinical Medicine 10(19), 4448, https://doi.org/10.3390/jcm10194448
Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. (2018) Modern iron replacement therapy: clinical and pathophysiological insights, International Journal of Hematology 107(1): 16-30, https://doi.org/10.1007/s12185-017-2373-3
Lo JO, Benson AE, Martens KL et al. (2023) The role of oral iron in the treatment of adults with iron deficiency. European Journal of Haematology 110(2): 123-130, https://doi.org/10.1111/ejh.13892
Wu TW, Tsai FP (2016) Comparison of the Therapeutic Effects and Side Effects of Oral Iron Supplements in Iron Deficiency Anemia, Drug Research 66: 257–261, https://doi.org/10.1055/s-0035-1569326
Celis AI, Relman DA, Huang KC. (2023) The impact of iron and heme availability on the healthy human gut microbiome in vivo and in vitro. Cell Chemical Biology 30(1):110-126.e3, https://doi.org/10.1016/j.chembiol.2022.12.001
Kolars B, Minakovic I, Grabovac B, Zivanovic D, Jovin VM (2024) Treatment Adherence and the Contemporary Approach to Treating Type 2 Diabetes Mellitus. Biomedical Papers of Medical Faculty of the University Palacky 168, 97–104, https://doi.org/10.5507/bp.2024.009
Melina V, Craig W, Levin S (2016) Position of the Academy of Nutrition and Dietetics: Vegetarian Diets, Journal of the Academy of Nutrition and Dietetics 116(12), 1970–1980, https://doi.org/10.1016/j.jand.2016.09.025
Stoffel N.U.; von Siebenthal H.K.; Moretti D.; Zimmermann M.B. (2020) Oral Iron Supplementation in Iron-Deficient Women: How Much and How Often? Molecular Aspects of Medicine 75, 100865, https://doi.org/10.1016/j.mam.2020.100865
Hamano H, Niimura T, Horinouchi Y, et al. (2020) Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Toxicology Letters 318: 86-91, https://doi.org/10.1016/j.toxlet.2019.10.016
Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. (2023) Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. Pharmaceuticals 16, 847, https://doi.org/10.3390/ph16060847
van Santen S, de Mast Q, Oosting JD, et al. (2014) Hematologic parameters predicting a response to oral iron therapy in chronic inflammation. Haematologica 99(9): e171-173, https://doi.org/10.3324/haematol.2014.106799
Dignass AU, Gasche C, Bettenworth D, et al. (2015) European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. Journal of Crohn's and Colitis 9(3): 211-222, https://doi.org/10.1093/ecco-jcc/jju009
Okam MM, Koch TA, Tran MH. (2017) Iron supplementation, response in iron-deficiency anemia: analysis of five trials. The American Journal of Medicine 130(8): 991.e1 - 991.e8, https://doi.org/10.1016/j.amjmed.2017.03.045
Gamad N, Saha PK, Sharma P, Suri V, Chakrabarti A, Saha L. (2021) A randomized controlled trial comparing the efficacy, tolerability, and cost of oral iron preparations in iron-deficiency anemia in pregnancy. The Journal of Obstetrics and Gynaecology Research 47(11): 3828-3841, https://doi.org/10.1111/jog.14999
Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. (2015) Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 10(2):e0117383, https://doi.org/10.1371/journal.pone.0117383
Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. (2013) Tolerability of different oral iron supplements: a systematic review. Current Medical Research and Opinion 29 (4), 291–303, https://doi.org/10.1185/03007995.2012.761599
Fabiano A, Brilli E, Fogli S, Beconcini D, Carpi S, Tarantino G, Zambito Y. (2018) Sucrosomial® iron absorption studied by in vitro and ex-vivo models. European Journal of Pharmaceutical Sciences 111: 425–431, https://doi.org/10.1016/j.ejps.2017.10.021
Gómez-Ramírez S, Brilli E, Tarantino G, Munoz M (2018) Sucrosomial® iron: a new generation iron for improving oral supplementation, Pharmaceuticals 11(4): 97 https://doi.org/10.3390/ph11040097
Ciudin A, Simo-Servat O, Balibrea JM, et al. (2018) Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER Study. Endocrinología, Diabetes y Nutrición (England Edition) 65(1):17-20, https://doi.org/10.1016/j.endinu.2017.10.007
Giordano, G.; Napolitano, M.; Di Battista, V.; Lucchesi, A. (2021) Oral High-Dose Sucrosomial Iron vs Intravenous Iron in Sideropenic Anemia Patients Intolerant/Refractory to Iron Sulfate: A Multicentric Randomized Study.Annals of Hematology 100: 2173–2179, https://doi.org/10.1007/s00277-020-04361-3
Bastida G, Herrera-de Guise C, Algaba A, et al. (2021) Sucrosomial iron supplementation for the treatment of iron deficiency anemia in inflammatory bowel disease patients refractory to oral iron treatment. Nutrients 13(6): 1770, https://doi.org/10.3390/nu13061770
Abbati G, Incerti F, Boarini C, Pileri F, Bocchi D, Ventura P, Buzzetti E, Pietrangelo A (2019) Safety and Efficacy of Sucrosomial Iron in Inflammatory Bowel Disease Patients with Iron Deficiency Anemia. Internal and Emergency Medicine 14, 423–431, https://doi.org/10.1007/s11739-018-1993-9
Mafodda A, Giuffrida D, Prestifilippo A, et al. (2017) Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care in Cancer 25(9):2779-2786. https://doi.org/10.1007/s00520-017-3690-z
Bertani L et al. ( 2021) Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis, Nutrients 13, 608. https://doi.org/10.3390/nu13020608
Elli L et al. (2018) Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study, Nutrients 10(3): 330; https://doi.org/10.3390/nu10030330
Howaldt S, Domenech E, Martinez N, Schmidt C, Bokemeyer B. (2022) Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial. Inflammatory Bowel Diseases 28(3): 373-384, https://doi.org/10.1093/ibd/izab073
Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A (2015) Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program. Inflammatory Bowel Diseases 21(3): 579–588, https://doi.org/10.1097/mib.0000000000000314
Schmidt C, Ahmad T, Tulassay Z, et al. (2016) Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study, Alimentary Pharmacology and Therapeutics 44(3): 259-270, https://doi.org/10.1111/apt.13665
Pergola PE, Kopyt NP (2021) Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. American Journal of Kidney Diseases 78(6): 846-856.e1, https://doi.org/10.1053/j.ajkd.2021.03.020
Pisani A, Riccio E, Sabbatini M, et al. (2015) Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation 30(4): 645-652, https://doi.org/10.1093/ndt/gfu357
Cesarano D, Borrelli S, Campilongo G, D’Ambra A, Papadia F, Garofalo C, De Marco A, Marzano F, Ruotolo C, Gesualdo L et al. (2024) Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency Nutrients 16(9): 1255; https://doi.org/10.3390/nu16091255
de Alvarenga Antunes CV, de Alvarenga Nascimento CR, Campanha da Rocha Ribeiro T, de Alvarenga Antunes P, de Andrade Chebli L, Martins Gonçalves Fava L, Malaguti C, Maria Fonseca Chebli J (2020) Treatment of Iron Deficiency Anemia with Liposomal Iron in Inflammatory Bowel Disease: Efficacy and Impact on Quality of Life. International Journal of Clinical Pharmacy 42(3): 895-902, https://doi.org/10.1007/s11096-020-01044-x
Maladkar M, Sankar S, Yadav A, Maladkar M, Sankar S, Yadav A (2020) A Novel Approach for Iron Deficiency Anaemia with Liposomal Iron: Concept to Clinic, Journal of Biosciences and Medicines 8(9): 27–41, https://doi.org/10.4236/jbm.2020.89003
Biniwale P, Pal B, Sundari T, Mandrupkar G, Datar N, Khurana AS, Qamra A, Motlekar S, Jain R, Biniwale P et al. (2018) Liposomal Iron for Iron Deficiency Anemia in Women of Reproductive Age: Review of Current Evidence. Open Journal of Obstetrics and Gynecology 8(11): 993–1005, https://doi.org/10.4236/ojog.2018.811100
Bengelloun Zahr S, Allata Y, El Mansoury M et al. (2024) Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-dialysis Chronic Kidney Disease Patients: A Non-inferiority Study. Cureus 16(9): e70114, https://doi.org/10.7759/cureus.70114
Duque X, Martinez H, Vilchis-Gil J et al. (2014) Effect of supplementation with ferrous sulfate or iron bis-glycinate chelate on ferritin concentration in Mexican schoolchildren: a randomized controlled trial. Nutrition Journal 13: 71 https://doi.org/10.1186/1475-2891-13-71
Milman N, Jønsson L, Dyre P et al. (2014) Ferrous bisglycinate 25 mg iron is as effectiveas ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. Journal of Perinatal Medicine 42 (2):197–206. https://doi.org/10.1515/jpm-2013-0153
Name JJ, Vasconcelos ARAR, Valzachi Rocha Maluf MC. (2018) Iron bisglycinate chelate and polymaltose iron for the treatment of iron deficiency anemia: a pilot randomized trial. Current Pediatric Reviews 14(4) :261–268, https://doi.org/10.2174/1573396314666181002170040
Fischer Jordie AJ, Cherian AM, Bone JN, Karakochuk CD (2023) The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials, Nutrition Reviews 81(8), 904–920, https://doi.org/10.1093/nutrit/nuac106
Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR (2022) Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. Nutrients 14 (3), 452, https://doi.org/10.3390/nu14030452
Views:
68
Downloads:
3
Copyright (c) 2026 Anastasiia Holoborodko, Ewa Wieczorkiewicz, Patrycja Stępińska, Eliza Garbacz, Agnieszka Pocheć, Bartosz Lautenbach, Dariusz Nędza, Klaudia Wojciech, Anhelina Loputs, Wiktoria Błaszczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
